Conexeu Sciences Inc. (NASDAQ: CNXU) announced the completion of its 12‐month P.R.O.O.F preclinical study, meeting objectives across facial, body, and mechanical performance pillars. The results support advancing the single‐formulation CXU platform toward a predicate‐based 510(k) submission, targeted for Q1 2027.